



ASX/MEDIA RELEASE

28 May 2018

Varian Interlocutory Application Update

In its announcement of 22 May 2018, Sirtex Medical Limited (ASX:SRX) (**Sirtex**) advised that Varian Medical Systems, Inc. (**Varian**) had filed an application in the Federal Court of Australia concerning the scheme of arrangement with Varian (**Varian Scheme**) seeking orders that the shareholder meeting be re-convened on 31 May 2018.

Varian's application was heard on Friday, 25 May 2018 with the Court indicating that it anticipates to make orders consistent with the indicative timetable submitted by Sirtex, which includes relisting the proceedings concerning the Varian Scheme before the Court on 3 July 2018 for the purpose of considering whether to approve supplementary disclosure to be sent to shareholders in relation to the Varian Scheme.

If approved, a date will be set later in July for the scheme meeting to be held.

At this time, the Directors of Sirtex continue to unanimously support and recommend the Varian Scheme. Sirtex anticipates that the new timetable will allow sufficient time for the board to complete its assessment of the offer received from CDH Genetech Limited on 22 May 2018 for the acquisition of all of the shares in Sirtex by way of scheme of arrangement (**CDH Proposal**) and the relative merits and risks of the CDH Proposal and the Varian Scheme.

- ENDS -

About Sirtex Medical, www.sirtex.com

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with over 86,000 doses supplied and administered at over 1,160 medical centres in more than 40 countries.

Investor Enquiries:

Mr Andrew McLean
CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Head of Investor Relations &
Corporate Development
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

To subscribe to our email alert service for ASX Announcements, please visit:

<http://www.sirtex.com/au/investors/email-alerts/>

Follow us on Twitter: **@sirtexmedical**

Visit us on LinkedIn: **Sirtex Medical Limited**

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406